Opening Asia for Russia

China is testing 16 more COVID-19 vaccines

19.02.2021 113 просмотров

The National Medicines Administration of the People's Republic of China (NMPA) has issued an emergency approval for clinical trials of 16 coronavirus vaccines based on 5 process routes. 

Of the 16 vaccine candidates, 6 are already in phase 3 clinical trials.

16 Vaccines 3.jpg

Amid the coronavirus epidemic, the NMPA launched the central control of anti-epidemic drugs and medical devices, actively promotes the research, development and market launch of COVID-19 vaccines, and approves drugs for the treatment of coronavirus and protective equipment from it for emergency use in the country, says the Chinese drug regulator.

The NMPA has now given conditional approval for the use of two domestically produced COVID-19 vaccines.

16 vaccines 1.jpg

The agency also issued an emergency permit to conduct clinical trials of 22 drugs for the treatment for COVID-19 and coronavirus-related indications by granting conditional market approval for two drugs.

In addition, the NMPA has granted emergency use approval for 54 test reagents, with a daily production capacity of up to 24 million doses.

16 vaccines 2.jpg

In addition, the agency also granted emergency approval for the issuance of 420 certificates for the production of medical protective suits and 307 certificates for the production of medical protective masks.

Новости партнёров